Jian Costa

Data censorship is an essential angle; it directly affects the reliability of KS test interpretation and the necessary caution. We must therefore establish a censored data management protocol before any analysis, thus conditioning the validity of our statistical conclusions. Otherwise, any decision based on these tests would be compromised.

Let's avoid rushing to hasty conclusions, because performing a Kolmogorov-Smirnov test does not guarantee the realization of a statistical similarity.
The validity of results is always conditional on critical assumptions, notably the relevance of the benchmark.
If the reference model does not reflect market specifics, such as restricted liquidity or capitalization structure in Canada, conclusions can be misleading.
For example, a KS test on Canadian private equity portfolios, heavily concentrated, compared to an inappropriate global benchmark, could give a false impression of similarity, without protecting against a real drawdown.

Before any conviction, the simple execution of Kolmogorov-Smirnov tests does not guarantee a robust realization of statistical similarity, especially if the underlying conditions of the distributions are not rigorously aligned.
The KS test measures the maximum distance between two cumulative distribution functions, but it is less sensitive to differences in the distribution tails.
These tails are crucial for assessing extreme risks in venture capital portfolios, often characterized by rare but impactful events.
If the reference distribution does not faithfully reflect these characteristics, like the "black swans" in energy markets in Canada, the test may indicate a misleading similarity.
The strength of this realization is therefore conditional on a perfect model fit, which is rarely the case in practice.

Let's not jump to conclusions; the realization via Kolmogorov-Smirnov tests is not a decisive proof in itself.
The downside lies in the quality of underlying data; a KS test, however relevant, does not correct flawed information.
If the data come from a market with speculative bubbles, like Japan's zero-yield policy, the distributional similarity could be an artifact rather than proof of robustness.
For example, KS tests on Japanese venture capital data from euphoric periods risk validating strategies based on illusory correlations, an exit condition we must always anticipate.

Avoid rushing into hasty conclusions; performing Kolmogorov-Smirnov tests does not guarantee the realization of the methodology if the data quality is not impeccable. The downside is that statistically significant results could be misleading if the underlying distributions are non-stationary or if biases persist. Before conviction, one must evaluate the conditions that would invalidate the tests, such as too short historical data or changing market regimes. For example, applying these tests to venture fund performances without considering cohort effects or economic cycles could mask a future drawdown. The fail-safe is not in the tool but in the robustness of the prior hypotheses assessment.

Let us avoid rushing into hasty conclusions; performing Kolmogorov-Smirnov tests alone does not guarantee a reliable evaluation of statistical similarity if input conditions are not robust.
The validity of this realization is intrinsically linked to data quality and the relevance of thresholds chosen, a crucial point for any fund manager.
If empirical data come from a non-representative sample or reference data are poorly defined, an unexpected drawdown could occur.
For example, comparing Canadian venture capital portfolios to global indices without adjusting for local structural biases risks creating an illusion of convergence, ignoring specific geographical risks.
The mandate of fail-safe requires extreme caution in such interpretations that could mask underlying weaknesses.

Performing Kolmogorov-Smirnov tests alone is not enough to concretize statistical reliability; it only validates a distribution similarity under specific conditions.
The exit condition comes first, because the validity of a test depends on data quality and underlying assumptions.
If the data are biased or if the stationarity assumptions are violated, the test confirms a similarity in a potentially flawed framework.
For example, comparing venture capital portfolio performances without adjusting for selection biases could mask divergent real performances, leading to suboptimal capital allocation.

Before any conviction, it is imperative to consider the downside; simply performing Kolmogorov-Smirnov tests does not guarantee a reliable realization of statistical similarity.
If the underlying assumptions of the test are not rigorously validated, especially for heavy-tailed data like venture capital returns, the result can be misleading.
A scenario where a test indicates similarity, while the reference model is inadequate, represents a significant drawdown in analysis.
The mandate of a fund manager is to always anticipate what protects us if the test fails, through critical analysis of the underlying distributions and their limits.
For example, ignoring the propensity for extreme events in venture capital portfolios could lead to an interpretation of similarity while substantial deviations persist.

Performing Kolmogorov-Smirnov tests is one thing, but verifying lower-rank anomalies that you mention is the sine qua non condition to truly validate similarity. It is essential to incorporate this lower-rank control before any conclusion, as this is where the most subtle and potentially riskiest differences hide. Without this, the similarity test loses its predictive power and opens the door to critical misinterpretation errors.

Let's avoid rushing to conclusions about the concretization of statistical similarity via Kolmogorov-Smirnov (KS) tests when empirical data are intrinsically biased.
The exit condition comes first: if reference distributions are built on abnormally calm market periods, this masks real downside risks.
A statistical similarity does not protect us against a localized tail risk if the global benchmark does not account for sector-specificities or provincial regulations.
For example, a Canadian natural resources portfolio compared to a global benchmark that omits systemic shocks specific to Canada does not reflect the reality of the mandate.

Before rushing to the conclusion that Kolmogorov-Smirnov tests 'materialize' statistical similarity, one must assess the risk of methodological deception.
What is at stake here is the validity of a proof, not merely the execution of a procedure.
If the underlying benchmark is flawed, such as using a normal distribution for venture capital returns that are intrinsically asymmetric, then applying the KS test, even if performed with rigor, will not guarantee a valid conclusion.
The downside of such an approach is relying on an illusory similarity, ignoring the actual tail risks that may occur.
For example, a KS test that validates the similarity between a venture capital portfolio's returns and a Gaussian benchmark model is false security because it masks the impact of extreme events that dominate real venture capital returns.

Before any conviction, failure risks must be analyzed.
Performing Kolmogorov-Smirnov tests, although crucial, does not guarantee the realization of statistical similarity if the data or thresholds are fundamentally flawed.
If the reference distributions do not account for the asymmetric and heavy-tailed nature of venture capital returns, the test could indicate a similarity that masks a fundamental divergence.
For example, comparing venture capital performance to a standard normal distribution, ignoring extreme events, would lead to false conclusions about true performance.
The mandate is to guard against illusory conclusions, not to confirm them hastily.